Novavax (NVAX) Current Deferred Revenue (2010 - 2026)

Novavax's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $400.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 22.76% year-over-year to $400.0 million; the TTM figure through Mar 2026 stood at $400.0 million (down 22.76% YoY), while the FY2025 annual figure was $140.1 million, down 87.52% from the prior year.
• Current Deferred Revenue was $400.0 million for Q1 2026 at Novavax, up from $140.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.5 billion in Q1 2022 to a low of $140.1 million in Q4 2025.
• Historically, Current Deferred Revenue has averaged $876.1 million across 5 years, with a median of $863.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue soared 86.68% in 2022, then slumped 87.52% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $549.6 million in 2022, then surged by 57.13% to $863.5 million in 2023, then grew by 29.92% to $1.1 billion in 2024, then plunged by 87.52% to $140.1 million in 2025, then soared by 185.61% to $400.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $400.0 million (Q1 2026), $140.1 million (Q4 2025), and $500.0 million (Q3 2025), per Business Quant data.